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Objective: MiR-146a exerts negative control on inﬂammatory responses by suppressing cytokine-
induced expression of interleukin-1 receptor-associated kinase-1 (IRAK1) and tumor necrosis factor
receptor-associated factor 6 (TRAF6) by impairing NF-kB activity and inhibiting the expression of target
genes. Recent study suggests that histone deacetylases (HDACs) are involved in the regulation of
microRNA (miRNA) expression. Therefore, we determined whether HDAC inhibitors can increase miR-
146a expression, thereby inhibiting interleukin-1b (IL-1b)-induced signaling in osteoarthritis
ﬁbroblast-like synoviocytes (OA-FLS).
Method: MiRNA expression was analyzed using real-time PCR. IL-1b-induced downstream signals and
cytokine expression were evaluated using Western blotting and ELISA. Transcription factors regulating
promoter activation were identiﬁed using chromatin immunoprecipitation assays.
Results: IL-1b treatment of OA-FLS induced a mild (1.7-fold) increase in miR-146a expression that was
unable to appropriately downregulate IRAK1 and TRAF6 expression. HDAC inhibitors, SAHA (vorinostat),
and LBH589 (panobinostat) signiﬁcantly (6.1- and 5.4-fold) elevated miR-146a expression by increasing
the binding of the transcription factor NF-kB to the miR-146a promoter, and negatively regulated IL-1b-
induced IKK/IkB/p65 phosphorylation signaling and IL-6 secretion. The increase in miR-146a expression
induced by the HDAC inhibitors was prevented by transfection of miR-146a inhibitor or HDAC1 (class I
HDAC), HDAC4 (class IIa HDAC), and HDAC6 (class IIb HDAC) overexpression, suggesting that they were
due to inhibition of HDAC activity.
Conclusions: Our study demonstrated that HDAC inhibitor treatment in OA-FLS signiﬁcantly increased
miR-146a expression and mediated markedly negative regulation to inhibit IL-1b-induced signaling and
cytokine secretion. Our results indicate the potential rationale of anti-inﬂammatory effects for HDAC
inhibitors.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Recent studies indicate that novel genetic regulators, microRNAs
(miRNAs), are involved in the development of the musculoskeletal
system and in OA pathogenesis1e3. MiRNAs are a class of endoge-
nous non-coding small RNAs that ﬁne-tune the expression of.R. Yang, School of Pharmacy,
Taipei, Taiwan. Tel: 886-2-
work.
s Research Society International. Pmultiple genes to regulate physiological functions and disease
processes. These miRNAs are known to play a role in mediating the
effects of the main risk factors for OA, such as aging and inﬂam-
mation, through control of target genes1e3. Transcription factors
(myoblast determination protein 1, myogenin, and nuclear factor
kB; NF-kB) can control transcription of primary miRNA transcripts,
which are processed by the enzyme Dorsha and its associated
protein DGCR8, to form the precursor miRNAs (pre-miRNAs)1. Pre-
miRNAs are processed by the endoribonuclease Dicer, to form
approximately 22-nucleotide-long miRNAs that bind to the 30-un-
translated region (UTR) of target messenger RNAs to block protein
translation or induce degradation of target mRNAs1,2. A recentublished by Elsevier Ltd. All rights reserved.
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changes in the expression level of miRNAs are associated with the
onset and progression of diseases (e.g., osteoarthritis)2,3. For
example, miR-155 has been found to promote the maturation of
dendritic cells5 and the proliferation of resident ﬁbroblasts as well
as inﬁltrating myeloid and lymphoid cells to amplify immune re-
sponses and contribute to the development of inﬂammatory
arthritis3,6. In contrast to miR-155, miR-146a has been shown to
exert a negative retro-control on inﬂammatory responses. The
human genome contains two miR-146 genes, miR-146a and miR-
146b, on chromosomes 5 and 10, respectively7. The structural dif-
ferences of these two miRNAs are limited. However, miR-146a and
miR-146b do not seem to be redundant in their biologic activity. In
addition, the transcription of both miR-146a and miR-146b are
stimulated following lipopolysaccharide stimulation, but only
mature miR-146a is produced, suggesting theymay have a different
post-transcriptional processing mechanism8. It is known that miR-
146a expression is induced by lipopolysaccharide and pro-inﬂam-
matory mediators through the NF-kB activation pathway, which in
turn downregulates inﬂammatory cascades by suppressing the
expression of interleukin-1 receptor-associated kinase-1 (IRAK1)
and tumor necrosis factor receptor-associated factor 6 (TRAF6).
IRAK1 and TRAF6 impair NF-kB activity and inhibit the expression
of NF-kB target genes such as IL-6, IL-8, interleukin-1b (IL-1b), and
TNF-a2,3,9. Interestingly, the miR-146a expression in OA synovial
tissue10 and OA cartilage samples is low11,12, and the mechanism is
unclear. Current studies indicated that synthetic miR-146a trans-
fected into human synovial cells13 or peripheral blood mono-
nuclear cells14 signiﬁcantly reduced production of IL-1-induced
inﬂammatory mediators13 or macrophage colony-stimulating fac-
tor (M-CSF), receptor activator of nuclear factor kappa-B ligand
(RANKL)-mediated osteoclastogenesis, and joint destruction12.
These results suggest the approaches to increase the expression of
miR-146a may be a useful strategy for the treatment of OA.
Recent research indicates that trichostatin A, an inhibitor of
histone deacetylases (HDACs), signiﬁcantly upregulates miR-146a
transcriptional activation by increasing the DNA-binding activity
of NF-kB in macrophages isolated from aged mice, suggesting that
HDACs are involved in the regulation of miR-146a expression15.
HDACs are involved in the posttranslational modulation of core
histone proteins or non-histone proteins. Recent proteomic ana-
lyses have shown that a substantial number of key signal trans-
duction components and transcription factors regulating immune
responses and inﬂammation serve as HDAC substrates16e18. HDACs
are not only closely related to the expression of inﬂammatory
cytokine-induced matrix metalloproteinases (MMPs) but also
inhibit expression of cartilage-speciﬁc proteins such as aggrecan19.
In addition, HDAC1 and 2 levels were reportedly elevated in OA
cartilage20. HDAC inhibitors suppress the HDAC activity and thus
promote gene transcription. HDAC inhibitors were initially evalu-
ated for their anti-cancer activity; however, recent proteomic an-
alyses have demonstrated that a substantial number of key signal
transduction components and transcription factors regulating im-
mune responses and inﬂammation also serve as HDAC sub-
strates17,18, leading to the evaluation of their anti-inﬂammatory
activity. Consequently, regulating the miRNA levels through HDAC
inhibitors has become a promising strategy for the treatment of
inﬂammatory diseases. In this study, we evaluated the induction of
miR-146a levels in osteoarthritis ﬁbroblast-like synoviocytes (OA-
FLS) by two HDACs inhibitors, SAHA (vorinostat) and LBH589
(panobinostat), which target class I and II HDACs but not class
III21,22, and determined whether their increase is through HDACs-
dependent regulation. We also investigated HDACs increasing
negative feedback control by suppressing IRAK and TRAF6
expression, and IL-6 levels.Method
Materials
SAHA and LBH589 of >98% purity were synthesized by Dr Jing-
Ping Liou. We used non-conjugated primary antibodies against
IRAK1, TRAF6, HDAC6 or b-actin (Epitomics Inc., Burlingame, CA,
USA), HDAC1, HDAC4, or histone H3 (Cell Signaling Technology,
Danvers, MA, USA), or acetyl-histone H3 Lys9/Lys18 (Millipore,
Temecula, CA, USA). The labeled secondary antibodies we used
were horseradish peroxidase (HRP)- or FITC-conjugated anti-
mouse or anti-rabbit IgG antibodies (Jackson ImmunoResearch Inc.,
West Grove, PA, USA). IL-6 ELISA kits were purchased from eBio-
science Inc. (San Diego, CA, USA). The plasmids HDAC1-Flag
(plasmid 13820), HDAC4-Flag (plasmid 13821), HDAC6-Flag
(plasmid 13823), A547 (plasmid 15091), IRAK1-UTR (plasmid
15095), IRAK1mut-UTR (plasmid 15096), TRAF6-UTR (plasmid
15093), TRAF6mut-UTR (plasmid 15094), and NFkBm2 (plasmid
15090) were purchased from Addgene Inc. (Cambridge, MA, USA).
TurboFect transfection reagent was obtained from Fermentas
(Burlington, Ontario, Canada). MiR-146a mimic and inhibitor were
purchased from GenePharma (Shanghai, China). Unless otherwise
stated, all other chemicals were from SigmaeAldrich (St. Louis, MO,
USA).
Cell culture
Non-inﬂamed synovial membrane tissue (referred as normal)
were obtained from young patients undergoing diagnostic knee
arthroscopy, and the human OA-FLS cells used in this study were
derived from the synovial tissues of patients with osteoarthritis
undergoing total joint replacement surgery. The Ethics Committee
of National Taiwan University Hospital approved the protocol (IRB
number: 201212019RINC), and the patients gave their written
informed consent. The cells were cultured in 100-mm dishes in
high glucose DMEM medium supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (FBS) (both from Invitrogen Life
Technologies, Carlsbad, CA, USA), 100 U/mL of penicillin, and
100 mg/mL of streptomycin (Biological Industries, Kibbutz Beit
Haemek, Israel) at 37C in a humidiﬁed atmosphere of 5% CO2 in air.
Cells from passages four to eight were used for the experiments.
Cell cytotoxicity (MTT) assay
Cell cytotoxicity was measured by the colorimetric 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
assay. Cells (1  104) in 100 mL of medium in 96-well plates were
incubated with vehicle or test compound for 48 h. After various
treatments, 1 mg/mL of MTT was added and the plates incubated at
37C for an additional 2 h, then the cells were pelleted and lysed in
100 mL of dimethyl sulfoxide and the absorbance at 550 nm
measured on a microplate reader.
Measurement of mRNA and miRNA expression
Total RNAwas isolated from synovial ﬁbroblasts using OmicZol
RNA Extract Reagent (Omics Bio, Taipei City, Taiwan). For detecting
IRAK1 and TRAF6, reverse transcription (RT) was performed with
50 ng of total RNA, using random primers and M-MLV Reverse
Transcriptase (Promega, Madison, Wisconsin, USA). Reactions
included10mL of FastStartUniversal SYBRGreenMaster (ROX) (Roche
Applied Sciences, Mannheim, Germany), 5 mL of cDNA, and 0.2 mL of
primer set for real-time PCR. The oligonucleotideprimers used for the
ampliﬁcationwere as follows: for human IRAK1 (GenBank Accession
No. NM_001569), 50-TACCTGCCCGAGGAGTACATCAA-30 (forward)
Fig. 1. MiR-146a expression in FLS from normal synovial tissue and OA-FLS. RNA was
isolated from normal FLS or OA-FLS and the miR-146a levels were analyzed by real-
time PCR. Horizontal lines indicate the mean and 95% conﬁdence intervals of the
values from ﬁve and nine different donors in normal FLS and OA-FLS, respectively.
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TRAF6 (GenBank Accession No. NM_145803), 50-AATGTTGGCC-
CAGGCTGTTCATAG-30 (forward) and 50-TAAGGCGACCCTC-
TAACTGGTGAAT-30 (reverse); GAPDH (GenBank Accession No.
NM_002046), 50-ATTCCACCCATGGCAAATTC-30 (forward) and 50-
TGGGATTTCCATTGATGACAAG-30 (reverse). For miRNAs detection,
10 ng of total RNA were reverse transcribed into cDNA using the
TaqMan MicroRNA Reverse Transcription Kit and TagMan MicroRNA
Assays (Applied Biosystems, Foster City, CA, USA) according to man-
ufacturer’s instructions. TaqMan Universal Master MiX II, (10 mL)
TaqMan MicroRNA Assays (1 mL) and of cDNA (2 mL) were mixed for
real-time PCR detection.
Real-time PCR was performed using an Applied Biosystems
7900HT Sequence Detection system (Applied Biosystems). Samples
for miRNAs detection were ampliﬁed in a 96-well plate at 95C for
10 min, followed by 40 cycles of 95C for 15 s, and 60C for 1 min;
other reverse transcription products were ampliﬁed at 50C for
2 min then 95C for 10 min, followed by 40 cycles of 95C for 15 s,
and 55C for 1 min. The U6B small nuclear RNA (RNU6B) or the
GAPDH gene was used as endogenous control to normalize differ-
ences in total RNA levels in each sample. A threshold cycle (Ct) was
observed in the exponential phase of ampliﬁcation, the relative
mRNA expression level was determined by calculating the DDCt
values and the fold change was expressed as 2DDCt.
ELISA assay
OA-FLS (2.5  104) were transfected with mimic and inhibitor
(1 mM) of miR-146a for 24 h or treated with SAHA (10 mM) or
LBH589 (3 mM) for 30 min before and during incubation with IL-1b
(10 ng/mL) for 24 h. The mediumwas collected and assayed for IL-6
using commercial ELISA kits.
Transfection and reporter gene assay
OA-FLS (5  104) were seeded 1 day before transfection. The
plasmids IRAK1-UTR, IRAK1mut-UTR, TRAF6-UTR, TRAF6mut-UTR,
A547 (miR-146a promoter), NFkBm2, HDAC1-Flag, HDAC4-Flag,
HDAC6-Flag (1 mg of each) and 1 mL of TurboFect transfection
reagent were mixed for 20 min at room temperature, added to the
cells, and the mixtures were incubated for 24 h at 37C in a hu-
midiﬁed atmosphere of 5% CO2 in air. For the reporter gene assay,
100 mL of reporter lysis buffer (Promega) was added, and the cells
were scraped off the dishes, centrifuged at 17,000 g for 30 s at 4C,
and the supernatants were collected. Aliquots of cell lysates (20 mL)
were placed in the wells of an opaque black 96-well microtiter
plate, then 40 mL of luciferase substrate (Promega) was added and
the luminescence was immediately measured in a microplate
luminometer (Beckman Coulter, Krefeld, Germany).
Immunoblot analysis
OA-FLS (1 106) were incubated for 10 min at 4C in lysis buffer
(20 mM HEPES, pH 7.4, 2 mM EGTA, 50 mM b-glycerophosphate,
0.1% Triton X-100, 10% glycerol, 1 mM DTT, 1 mg/mL of leupeptin,
5 mg/mL of aprotinin, 1 mM phenylmethylsulfonyl ﬂuoride, and
1 mM sodium orthovanadate), then scraped off the culture vessel,
incubated on ice for a further 10 min, and centrifuged at 17,000 g
for 30 min at 4C. Protein samples (80 mg) were electrophoresed on
SDS gels and transferred onto a nitrocellulose membrane, which
was blocked by incubation for 30 min at room temperature with 5%
fat-free milk in phosphate-buffered saline (PBS). Immunoblotting
was performed by overnight incubation at 4C with primary anti-
bodies in PBS, followed by incubation for 1 h at room temperature
with HRP-conjugated secondary antibodies, then bound antibodieswere measured using ECL reagent (Advansta Corp., Menlo Park, CA,
USA) and exposure to photographic ﬁlm.
Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation assays were performed ac-
cording to the manufacturer’s instructions (Upstate Biotechnology,
Lake Placid, NY). OA-FLS (1  107) were treated with SAHA or
LBH589 for 48 h, incubated with 1% formaldehyde to ﬁx proteine
DNA complexes, washed twice with ice PBS, and harvested. They
were then lysed with 300 mL of lysis buffer containing protease
inhibitors and sonicated to shear the DNA into approximately 200-
to 1000-bp DNA fragments. The samples were precleared with
protein A/G agarose/salmon sperm DNA slurry, and immunopre-
cipitation analysis was performed at 4C overnight using anti-
acetyl-histone H3 antibody, and ﬁnally, the antibody/chromatin
complexes were collected by incubation with protein A/G agarose.
Anti-mouse IgG was used as a control for nonspeciﬁc binding.
Immunoprecipitated DNA was analyzed by real-time PCR using
promoter-speciﬁc primer pairs for the two NF-kB binding sites, I
and II, in the miR-146a promoter: for NF-kB binding site I, we used
forward 50-CTT GAA AAG CCA ACA GGC TCG TTG-30 and reverse 50-
GCG GGC ATC TGC ATG GGT CT-30; for NF-kB binding site II, we used
forward 50-ACG GAG TAA GCT CCA GCC TCC C-30 and reverse 50-CAT
TCC GCA CCC AGC GAG CTA-30. The DNA puriﬁed from the sonicated
nuclear lysate was analyzed by real-time PCR using the same
primer sets. The resulting data were used as an input control.
Expression of a target DNA sequence was normalized to the input
DNA and reported as fold enrichment compared with the non-
treated control.
Data analysis
The data are expressed as mean with 95% conﬁdence intervals
and were analyzed using one-way ANOVA. When ANOVA showed
signiﬁcant differences between the groups, Tukey’s post hoc test
was used to determine the pairs of groups showing statistically
signiﬁcant differences. P value of<0.05 was considered statistically
signiﬁcant.
Results
Dysregulation of negative feedback of miR-146a in OA-FLS
Since miR-146a is linked to the pathophysiology of osteoar-
thritis13, we ﬁrst identiﬁed the expression of miR-146a in OA-FLS.
As shown as Fig. 1, the expression of miR-146a in OA-FLS is
slightly (1.3-fold) higher than that in FLS from normal synovial
tissue; however, the difference between the two cells is not sta-
tistically signiﬁcant. Previous studies indicated that miR-146a
expression was inducible in response to the application of
Table I
The miR-146a and IRAKI, TRAF6 mRNA expression (fold) in response to IL-1b treatment in normal FLS and OA-FLS with different time periods
miR-146a P-value IRAKI P-value TRAF6 P-value
FLS
e 1.005 (0.987e1.023) 1.001 (0.989e1.013) 1.117 (1.000e1.234)
1 h 2.472 (1.434e3.511) 0.04* 3.216 (2.250e4.182) <0.001* 5.301 (4.266e6.336) <0.001*
6 h 2.921 (1.335e4.507) 0.02* 1.366 (0.508e2.224) 0.14*, <0.001y 3.689 (1.986e5.392) <0.001*, 0.03y
12 h 4.231 (3.547e4.915) 0.003* 1.028 (0.175e1.881) 0.89*, <0.001y 1.588 (1.502e1.674) 0.06*, 0.002y
24 h 7.005 (3.366e10.644) <0.001* 1.173 (0.322e2.024) 0.43*, <0.001y 0.977 (0.215e1.739) 0.54*, <0.001y
48 h 6.992 (3.504e10.480) <0.001* 0.782 (0.224e1.340) 0.07*, <0.001y 1.265 (0.711e1.819) 0.71*, <0.001y
72 h 5.862 (1.270e10.454) <0.001* 0.819 (0.328e1.310) 0.13*, <0.001y 1.386 (1.039e1.733) 0.46*, <0.001y
OA-FLS
e 1.039 (0.756e1.322) 0.954 (0.681e1.227) 1.027 (1.002e1.056)
1 h 1.436 (0.731e2.141) 0.16* 1.674 (1.177e2.171) 0.03* 1.760 (1.532e1.988) 0.02*
6 h 1.640 (0.849e2.431) 0.04* 2.314 (1.302e3.326) 0.01* 2.095 (1.359e2.831) 0.01*
12 h 1.043 (0.732e1.354) 0.82* 2.964 (2.155e3.773) 0.003* 2.603 (1.289e3.917) 0.007*
24 h 1.665 (1.398e1.932) 0.02* 2.801 (1.529e4.073) 0.009* 2.949 (1.647e4.251) 0.002*
48 h 1.173 (0.778e1.568) 0.36* 2.641 (1.373e3.909) 0.01* 2.307 (1.675e2.939) 0.01*
72 h 1.677 (0.984e2.370) 0.02* 2.439 (1.522e3.356) 0.02* 2.165 (1.574e2.756) 0.02*
The results represent the mean with 95% conﬁdence intervals for four separate experiments.
* P means comparing with non-treated control.
y P means comparing with individual 1 h group.
Table II
The luciferase expression (fold) in FLS or OA-FLS which transfected with IRAKI-UTR, IRAKI-mut UTR or TRAF6-UTR, TRAF6-mut UTR, then incubated with IL-1b for different
time periods
IRAKI-UTR IRAK1-mut UTR P-value* TRAF6-UTR TRAF6-mut UTR P-valuey
FLS
1 h 0.949 (0.736e1.163) 1 0.36 0.964 (0.805e1.124) 1 0.57
6 h 0.796 (0.533e1.059) 1 0.03 0.585 (0.437e0.732) 1 0.06
12 h 0.613 (0.356e0.871) 1 0.008 0.464 (0.411e0.517) 1 <0.001
24 h 0.476 (0.272e0.679) 1 <0.001 0.459 (0.351e0.568) 1 <0.001
48 h 0.387 (0.233e0.541) 1 <0.001 0.438 (0.390e0.486) 1 <0.001
72 h 0.323 (0.010 to 0.657) 1 <0.001 0.426 (0.341e0.512) 1 <0.001
OA-FLS
1 h 1.018 (0.912e1.124) 1 0.61 0.931 (0.755e1.108) 1 0.26
6 h 0.987 (0.840e1.134) 1 0.79 0.951 (0.732e1.169) 1 0.49
12 h 0.947 (0.776e1.118) 1 0.36 0.967 (0.813e1.121) 1 0.52
24 h 0.949 (0.758e1.141) 1 0.43 0.959 (0.769e1.149) 1 0.52
48 h 0.927 (0.810e1.044) 1 0.19 0.957 (0.763e1.152) 1 0.51
72 h 0.962 (0.808e1.115) 1 0.46 0.954 (0.868e1.039) 1 0.93
The results represent the mean with 95% conﬁdence intervals for four separate experiments.
* P means comparing IRAK1-UTR and IRAK1-mut UTR groups.
y P means comparing TRAF6-UTR and TRAF6-mut UTR groups.
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ensued, involving the downregulation of IRAK1 and TRAF6, two
known miR-146a target proteins3,7,23. We next determined
whether cytokine-induced miR-146a still possesses negative feed-
back functions in FLS. FLS from normal synovial tissue, treated with
IL-1b (10 ng/mL) for different time periods, showed a signiﬁcant
increase in miR-146a levels starting at 1 h, peaking at 24 h and
lasting till at least 72 h. On the other hand, IRAK1 and TRAF6 mRNA
expression peaked after IL-1b treatment for 1 h and then decreased
at longer time periods, suggesting that the increase in miR-146a
expression triggered a negative regulation of IRAK1 and TRAF6
mRNA expression in normal FLS [Table I]. In contrast, IL-1b treat-
ment in OA-FLS mediated only a mild (1.7-fold) miR-146a increase.
This miR-146a increase was unable to appropriately downregulate
IRAK1 and TRAF6 mRNA expression because IL-1b treatment
signiﬁcantly increased IRAK1 and TRAF6 mRNA levels in different
time periods [Table I]. To determine whether the change in IRAK1
and TRAF6 levels was regulated by miR-146a, we transfected FLS
and OA-FLS with plasmids that contained the ﬁreﬂy luciferase gene
fused to 30UTRs of IRAK1 (IRAK1-UTR) and TRAF6 (TRAF6-UTR), or
fused to mutant 30UTRs from IRAK1 (IRAK1-mut UTR) and TRAG6
(TRAF6-mut UTR) that contain 4-bp substitutions in the miR-146a
target sites, respectively. Administration of IL-1b in FLS resultedin a time-dependent reduction in luciferase levels in both the
IRAK1-UTR and TRAF6-UTR groups, but no signiﬁcant changes in
the IRAK1mut-UTR and TRAF6mut-UTR groups [Table II]. However,
no corresponding ﬂuctuation was observed in OA-FLS that had
been transfected with IRAK1-UTR, IRAK1mut-UTR, TRAF6-UTR, and
TRAF6mut-UTR plasmids in response to IL-1b treatment [Table II].
These results clearly indicate that the IL-1b-mediated miR-146a
increase is weaker in OA-FLS than in normal FLS and that these
low levels of miR-146a in OA-FLS were unable to appropriately
downregulate IRAK1 and TRAF6 expression.
HDAC inhibitors treatment signiﬁcantly increased miR-146a
expression in OA-FLS
Because HDAC inhibitors have been shown to exhibit anti-
arthritic activity, we investigated whether HDAC inhibitors can
increase miR-146a expression in OA-FLS. OA-FLS treatedwith SAHA
(10 mM) for 24 h displayed signiﬁcantly increased miR-146a
expression that lasted until 72 h [Fig. 2(A)]. LBH589 (3 mM) treat-
mentmarkedly elevatedmiR-146a levels, which peaked at 48 h and
lasted until at least 72 h. This increase was evident in experiments
containing >10 mM SAHA or >1 mM LBH589 [Fig. 2(B)]. In addition,
no signiﬁcant cytotoxicity resulted from SAHA (0.1e100 mM) or
Fig. 2. HDAC inhibitors increased miR-146a expression in OA-FLS. OA-FLS were treated with HDAC inhibitors SAHA or LBH589 for different time periods (A; 10, 3 mM respectively) or
at different concentrations (B), for 48 h, as indicated, and miR-146a levels were measured by real-time PCR. (C) The viability of OA-FLS determined after 24 h treatment with
indicated concentrations of SAHA or LBH589, compared with the control group, using the MTT assay. (D) OA-FLS were transfected with A547 plasmid for 24 h, treated with SAHA or
LBH589 for different periods, and luciferase expression was determined. (E) The levels of histone H3 acetylation at NF-kB binding sites I and II in the miR-146a promoter were
analyzed using a chromatin immunoprecipitation assay. (F) OA-FLS were transfected with plasmid NF-kBm2 for 24 h, treated with SAHA or LBH589 for 48 h, and then the expression
of luciferase was determined. The results represent the mean with 95% conﬁdence intervals (three independent samples using three donors cells). Data were analyzed by with one-
way ANOVA followed by Tukey’s post hoc test. Exact aP and bP values mean comparing with individual non-treated group.
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Fig. 3. HDAC inhibitors exhibited negative regulation of IL-1b-inducing signaling and IL-6 production through increase in miR-146a expression. (A) OA-FLS treated with SAHA
(10 mM) or LBH589 (3 mM) for 24 h, and total cell lysates were subjected to Western blotting for the indicated proteins. (B) OA-FLS were transiently transfected with a miR-146a
mimic or a miR-146a inhibitor (10 nM each) for 24 h, and miR-146a levels in the cells were measured using real-time PCR. (CeE) OA-FLS were transfected with a miR-146a mimic or
a miR-146a inhibitor for 24 h prior to treatment with SAHA (10 mM) or LBH589 (3 mM) for another 48 h, followed by treatment with IL-1b (10 ng/mL) for 1 h. Supernatants were
assayed for IL-6 by ELISA (D, E), and the whole cell extracts were subjected to Western blotting for indicated proteins (C). The results represent the mean with 95% conﬁdence
intervals (three independent samples using three donors cells). Data were analyzed using one-way ANOVA followed by Tukey’s post hoc test. P value means comparing with
indicated group. Western blot are representative of experiments from three different donors with similar results.
J.H. Wang et al. / Osteoarthritis and Cartilage 21 (2013) 1987e19961992LBH589 (0.01e10 mM) treatment in OA-FLS [Fig. 2(C)]. Previous
studies have indicated that the NF-kB binding sites located within
the miR-146a promoter play a pivotal role in the induction of miR-
146a7. Next, we determinedwhether HDAC inhibitors increasemiR-
146a levels through regulation of NF-kB binding in its promoterregion. To address this question, we transfected OA-FLS with the
A547 plasmid, which includes two normal NF-kB binding sites in
the miR-146a promoter, treated them with SAHA (10 mM) or
LBH589 (3 mM) for different periods, and determined the relative
amount of luciferase expressed. Treatment of OA-FLS with 10 mM
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starting at 24 h, peaking at 48 h and lasting until 72 h [Fig. 2(D)].
This HDAC inhibitor-mediated increase in NF-kB binding to the
miR-146a promoter was further conﬁrmed using the ChIP assay,
which determined whether there was increased histone H3 acet-
ylation in the miR-146a promoter region. Inhibition of HDAC ac-
tivities by SAHA or LBH589 resulted in a signiﬁcant increase in
histone H3 acetylation on both NF-kB binding sites I and II of the
miR-146a promoter region [Fig. 2(E)]. In contrast, there was no
increase in luciferase activity when OA-FLS were transfected with
the NFkBm2 plasmid, which contains twomutated (inactive) NF-kB
binding sites in the miR-146a promoter, and then treated with
either of the HDAC inhibitors for 48 h [Fig. 2(F)]. These resultsFig. 4. HDAC1, HDAC4, and HDAC6 overexpression reduced SAHA and LBH589 inhibition of
encoding HDAC1-Flag, HDAC4-Flag, and HDAC6-Flag, and cell lysates were immunoblotted
HDAC4, and/or HDAC6 as in (A), followed by treatment with SAHA (10 mM) for another 48 h.
with miR-146a mimic (10 nM) for 24 h and transfected and SAHA treated as in (B). IL-1b (10
IRAK1 (C) and TRAF6 (D) were determined using real-time PCR. The results represent the me
Data were analyzed using one-way ANOVA followed by Tukey’s post hoc test. P value means
three different donors with similar results.clearly indicate that HDAC inhibitor-induced miR-146a expression
is associated with enhanced binding capacity of NF-kB to the miR-
146a promoter in OA-FLS.
Next, we investigated whether the HDAC inhibitor-mediated
miR-146a increase could negatively regulate IL-1b activation
signaling. SAHA and LBH589 treatment for 24 h signiﬁcantly
increased acetyl-histone 3 levels in OA-FLS [Fig. 3(A)]. In addition,
OA-FLS transiently transfected with miR-146a mimic for 24 h
signiﬁcantly increased miR-146a expression [Fig. 3(B)]; in contrast,
transfection of OA-FLS with miR-146a inhibitor markedly inhibited
miR-146a levels [Fig. 3(B)], suggesting that the miR-146amimic can
increase miR-146a expression and that the inhibitor can decrease
miR-146a expression. Furthermore, incubation of OA-FLS with IL-IRAK1 and TRAF6 expression. (A) OA-FLS were transfected for 24 h with 1 mg of vector
for the indicated proteins. (B) OA-FLS were transfected with vectors encoding HDAC1,
Levels of miR-146a were measured using real-time PCR. (C, D) OA-FLS were transfected
ng/mL) was then added and incubation was continued for 1 h. Relative expression of
an with 95% conﬁdence intervals (three independent samples using three donors cells).
comparing with indicated group. Western blot are representative of experiments from
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and TRAF6 proteins and stimulated IKK/IkB/p65 phosphorylation.
The increases in these proteins levels and phosphorylation were
inhibited by SAHA (10 mM) or LBH589 (3 mM) pretreatment
[Fig. 3(C)]. To further determine if this HDAC inhibitor-mediated
inhibition is due to regulation of miR-146a levels, we transiently
transfected OA-FLS with either miR-146a mimic or miR-146a in-
hibitor for 24 h, treated with HDAC inhibitors for another 48 h, and
incubated with IL-1b for 1 h. The total lysates were collected for
Western blotting. [Fig. 3(C)] demonstrates that treatment with the
miR-146a inhibitor signiﬁcantly prevented SAHA or LBH589 inhi-
bition of IRAK1 and TRAF6 expression, and IKK/IkB/p65 phos-
phorylation. On the other hand, OA-FLS treated with the miR-146a
mimic exhibited similar inhibition with HDAC inhibitors. A similar
result was observed with IL-6 production. OA-FLS incubated with
IL-1b for 24 h showed a signiﬁcant increase in IL-6 production, and
this marked increase was inhibited in the presence of SAHA
[Fig. 3(D)] and LBH589 [Fig. 3(E)]. Furthermore, miR-146a inhibitor
treatment signiﬁcantly prevented SAHA or LBH589 inhibition of IL-
6 secretion, and miR-146a mimic treatment resembled inhibition
with HDAC inhibitors. These results indicated that HDAC inhibitors
increased miR-146a expression in OA-FLS, and this miR-146a in-
crease exhibited negative regulation of IL-1b-inducing signaling
and IL-6 production.HDAC inhibitors induced miR-146a increasing can be inhibited by
overexpression of HDACs
We next examined whether HDAC inhibitors increased miR-
146a expression by inhibiting HDAC activity. OA-FLS transfected
with HDAC1- (class I HDAC), HDAC4- (class IIa HDAC), or HDAC6
(class IIb HDAC)-encoding plasmid(s) expressed the expected iso-
form(s) [Fig. 4(A)]. The SAHA-induced increase in miR-146a was
inhibited in OA-FLS which overexpress HDAC1, HDAC4, and HDAC6,
and three HDACs-coexpressing OA-FLS exhibited further inhibition
[Fig. 4(B)]. Furthermore, SAHA-inhibited, IL-1b-induced IRAK1 and
TRAF6 expression was prevented in OA-FLS overexpressing HDACs
[Fig. 4(C) and (D)]. These results suggest that HDAC inhibitors in-
crease miR-146a expression by inhibiting the HDAC activity.
Finally, we examined whether treatment in OA-FLS with HDAC
inhibitors can regulate other miRNA involved in joint homeostasis.
We incubated OA-FLS with SAHA or LBH589 for 6e48 h, and then
measured the level of miR-155. No signiﬁcant changes in miR-155
expression were observed in response to HDAC inhibitors treat-
ment [Table III].Discussion
IRAK1 and TRAF6, the two key downstream adaptor molecules of
the Toll-like and IL-1 receptors pathway, are the molecular targets of
miR-146a. After activation by ligand-receptor binding, IRAK1/TRAF6
recruits the TAK1/TAB2/TAB3 complex, which subsequentlyTable III
MiR-155 expression (fold) in response to SAHA and LBH589 treatment in OA-FLS
with different time periods
SAHA P-value LBH589 P-value
e 1.003 (0.951e1.055) 1.012 (0.968e1.056)
6 h 1.011 (0.978e1.044) 0.61 1.161 (1.013e1.309) 0.12
12 h 1.049 (1.020e1.078) 0.11 1.023 (0.811e1.235) 0.72
24 h 1.073 (0.832e1.314) 0.29 1.065 (0.927e1.203) 0.48
48 h 1.020 (0.906e1.134) 0.59 1.025 (0.803e1.247) 0.71
The results represent the mean with 95% conﬁdence intervals for three separate
experiments.
P means comparing with individual control group.phosphorylates NF-kB7,12,15. Evidence shows that miR-146a can exert
negative control, inhibiting IRAK1 and TRAF67,12 expression,
impairing NF-kB activity, and suppressing NF-kB target gene, such as
IL-6, IL-8, and TNF-a6,11, expression. Transfectionwith synthetic miR-
146a signiﬁcantly suppresses extracellular matrix-associated pro-
teins in chondrocytes and inhibits inﬂammatory cytokines in syno-
vial cells from human knee joints13. In addition, overexpression of
miR-146a in cultured peripheral blood mononuclear cells from
healthy volunteers inhibited osteoclastogenesis, and intravenous
injection of miR-146a prevented joint destruction in mice model14.
Therefore, recent studies suggest that increasing miR-146a levels
may be an effective strategy for the treatment of inﬂammatory
arthritis2,6,11,18. Our results showed that OA-FLS treated with IL-1b
exhibited a mild miR-146a increase compared with FLS from normal
synovial tissue. This gentle miR-146a increase was unable to
downregulate IRAK1/TRAF6 expression and IL-1b-induced signaling
in OA-FLS. Interestingly, previous studies have reported similar ob-
servations in rheumatoid arthritis (RA) patients. Peripheral blood
mononuclear cells from RA patients exhibited increased miR-146a
production compared with control individuals; however, this
increased miR-146a could not reduce IRAK1 and TRAF6 levels
because their mRNA expression levels were very similar to those in
control individuals24. This impaired downregulation of IRAK1/TRAF6
by miR-146a contributed to prolonged TNF-a production and
arthritis progression2,3,23. Our results indicate that HDAC inhibitor
treatment of OA-FLS increased miR-146a expression and negative
regulation of IL-1b signaling and cytokine secretion, suggesting that
HDAC inhibitors are potent therapeutics for OA.
HDAC inhibitors, which act through multiple mechanisms, such
as induction of cancer cell apoptosis and cell cycle arrest, were
originally developed as anti-cancer agent17,25. Recent studies have
demonstrated that HDAC inhibitors exhibit anti-inﬂammatory ac-
tivity in different cells, including microglia26, monocyte/macro-
phages27, T cells28, dendritic cells29, and FLS30. However, our
understanding of the targets of HDAC inhibitors is limited. Recent
studies have indicated that several signal transduction components
and transcription factors that regulate inﬂammation could serve as
HDAC substrates16e18. The current view suggests that miRNA
expression is controlled at the transcriptional level31,32 and can be
regulated through epigenetic mechanisms. Zhang et al. reported that
Myc interacts with HDAC3 tethered to the miR-15a/miR-16-1 pro-
moter region33. HDAC3-mediated histone hypoacetylation and sup-
pressed miR-15a/miR-16-1 gene expression in mantle cell
lymphoma33, supporting the results obtained by treatment with
pan-HDAC inhibitor SAHA or HDAC3 siRNA that increased miR-15a/
miR-16-1 expression33. Similar results were observed in neuroblas-
toma. Research found that proto-oncogeneMYCN recruits HDAC2 to
the miR-183 promoter region and causes transcriptional repression
of miR-18334. Although the actual mechanism is yet to be elucidated,
HDAC2 inhibition by treatment with pan-HDAC inhibitor pan-
obinostat (LBH589), or depletion by siRNA, results in miR-183 in-
duction and triggers subsequent cell apoptosis, colony formation
inhibition in vitro, and xenograft growth suppression in mice34.
These results suggest that epigenetic regulation can affect primary
miRNA transcript production; however, HDAC isoforms that regulate
miRNA transcript are unknown. A literature review indicates that
more than two HDAC isoforms (classes I and II) may be involved in
miRNA transcriptional regulation33e35. Furthermore, previous
studies demonstrate that other types of miRNAmay be implicated in
the development of inﬂammatory arthritis, e.g., miR-155 increases
pro-inﬂammatory cytokines such as TNF-a, IL-6, IL-1b, IL-8 and de-
creases IL-1036 production; inhibition of miR-155 expression leads to
suppression of osteoclasts and increase in bone mass37. Our results
indicate that SAHA and LBH589 administration in OA-FLS signiﬁ-
cantly increased miR-146a levels, but not markedly change miR-155
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I), HDAC4- (class IIa), or HDAC6- (class IIb) encoding plasmids, which
overexpress each of these HDAC proteins, could signiﬁcantly inhibit
the HDAC inhibitor-induced increase in miR-146a levels. Co-
transfection of OA-FLS with HDAC1/4/6-encoding plasmids medi-
ated more substantial suppression of miR-146a levelsddown to
untreated levels [Fig. 4(B)]. These results suggest that class I/II HDACs
play important roles in the HDAC inhibitor-mediated increase in
miR-146a expression in OA-FLS. Whether other isoforms are
involved in miR-146a regulation or other species of miRNA expres-
sion requires further investigation.
Taken together, we found that OA-FLS treatment with IL-1b
induced mild miR-146a expression and insigniﬁcant IRAK1/TRAF6
downregulation. Our results indicate, for the ﬁrst time, that treat-
ment of OA-FLS with the HDAC inhibitors SAHA and LBH589
increased the transcription factor NF-kB binding to the miR-146a
promoter, subsequently increasing miR-146a expression, and
mediated a negative regulatory signal that decreased IRAK1/TRAF6
levels, IKK/IkB/p65 activation, and IL-6 secretion. In addition, the
HDAC inhibitor-induced miR-146a increase and IRAK1/TRAF6
downregulation can be prevented bymiR-146a inhibitor or HDAC1/
4/6 overexpression, suggesting that the mechanism underlying the
functioning of these inhibitors is the inhibition of HDAC activity.
This study demonstrates a potential rationale for the anti-
inﬂammatory effects of HDAC inhibitors and highlights their po-
tential use as therapeutics for inﬂammatory diseases.
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